Cataract & Refractive

Latest News


CME Content


ESBA105, an anti-TNF alpha antibody fragment designed to reduce inflammation in patients undergoing cataract surgery, has begun a Phase Ib/IIa trial, according to an announcement from ESBATech AG, the antibody's developer.

Ophthalmology Times Europe, in conjunction with Carl Zeiss Meditec, is to host a free online seminar aimed specifically at cataract and refractive surgeons, explaining how to integrate the Acri.LISA multifocal intraocular lens (IOL) into practice.

Prolacria (diquafosol tetrasodium ophthalmic solution) 2% has entered a Phase III trial for the treatment of dry eye disease, according to an announcement from the solution's developer, Inspire Pharmaceuticals, Inc.

No clear link between cataract surgery and progressive age-related macular degeneration (AMD) could be established by a study published in the February issue of Ophthalmology.

A New Drug Application (NDA) for ganciclovir ophthalmic gel 0.15% against herpetic keratitis, submitted by Sirion Therapeutics, Inc, has been accepted for review by the FDA.

Performing LASIK surgery that is customized for each eye can offer more pleasing outcomes in terms of both patient safety and comfort, claims Kerry K. Assil, MD.

Professor Michael Knorz discusses his experiments on the adhesion strength of flaps, comparing the femtosecond with the microkeratome.

ISTA Pharmaceuticals' dry eye candidate, ecabet sodium, has successfully completed Phase IIb testing and will soon be progressing to Phase III trials taking it a step closer to regulatory approval.

The Vision Care for Kids Bill of 2009, legislation to provide vision care to children without health insurance, has been introduced in the US after being approved both by the Senate and by the House of Representatives.

Phacoemulsification can increase visual acuity in uveitis patients, concluded a study published in the January issue of the British Journal of Ophthalmology.

The Tecnis multifocal intraocular lens (IOL) has been approved by the FDA, according to an announcement made by AMO, the manufacturer of the lens.

Testing the UK's eyes

"The Big Eye Test", a programme to provide privately-funded eye examinations to the general public, has been launched in the UK.

The Investigational New Drug (IND) application for NVC-422, a molecule under investigation by NovaBay Pharmaceuticals for the treatment of eye infections, has been cleared by the FDA, triggering a development milestone payment from Alcon to NovaBay of $1 million.

A great variety of fungal agents may cause endophthalmitis, and accurate diagnosis is essential for effective treatment, according to a study published in the November/December 2008 issue of Retina.

Alcon announces new CEO

As of March 31st this year, Cary Rayment will retire as president and chief executive officer of Alcon, Inc; he will be replaced on April 1st by Kevin Buehler.

Advanced Medical Optics (AMO) has been acquired by Abbott, a global pharmaceutical and medical device company, the companies have announced in a statement.

Cell apoptosis caused by free-radical formation during phacoemulsification can be mediated by the introduction of ascorbic acid, according to a study published in the December 2008 issue of the Journal of Cataract & Refractive Surgery.

Most candidates for cataract surgery have a degree of corneal astigmatism, which should be considered by intraocular lens (IOL) manufacturers, concluded a study published in the January issue of the Journal of Cataract & Refractive Surgery.

A long-term course of injections of botulinum toxin ("Botox") offers a viable treatment for complicated strabismus, according to study results published in the December 2008 issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus.